Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGLT2 Inhibitors, Ketones, and Cardiovascular Benefit
NCT05057806Phase 1Recruiting
- Sponsor
- UT Health San Antonio
- Start
- Jan 2021
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial in type 2 diabetes mellitus (T2DM) and heart failure (HF) comparing Empagliflozin Group with Placebo group (2 arms). Primary endpoints: Change in Phosphocreatine at 3 months, Change in Adenosine Triphosphate at 3 months and 3 more. Started Jan 2021; status: recruiting.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)heart failure (HF)
Beyond the preview
Go deeper on NCT05057806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05057806.